Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 246 articles:
HTML format
Text format



Single Articles


    June 2019
  1. AFKHAMI S, Lai R, D'Agostino MR, Vaseghi-Shanjani M, et al
    Single-dose mucosal immunotherapy with chimpanzee adenovirus-based vaccine accelerates TB disease control and limits its rebound following antibiotic cessation.
    J Infect Dis. 2019 Jun 13. pii: 5519039. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. ZHONG W, Levine MZ
    Stockpiled avian influenza A(H7N9) vaccines induce robust, non-neutralizing functional antibodies against antigenically drifted 5th wave A(H7N9) viruses.
    J Infect Dis. 2019 Jun 5. pii: 5511958. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. BOGAARDS JA, van der Weele P, Woestenberg PJ, van Benthem BHB, et al
    Bivalent HPV Vaccine Effectiveness Correlates with Phylogenetic Distance from Hpv Vaccine Types 16 And 18.
    J Infect Dis. 2019 Jun 4. pii: 5511346. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. REIF DM, Chanock SJ, Edwards KM, Crowe JE, et al
    Inappropriate Citation of Vaccine Article.
    J Infect Dis. 2019 Jun 3. pii: 5510417. doi: 10.1093.
    PubMed     Text format    


    May 2019
  5. MARTINEZ-BAZ I, Navascues A, Casado I, Aguinaga A, et al
    Remaining effect of influenza vaccines received in prior seasons.
    J Infect Dis. 2019 May 20. pii: 5492310. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. ZAUBERMAN A, Gur D, Levy Y, Aftalion M, et al
    Post-exposure administration of a Yersinia pestis live vaccine potentiates second-line antibiotic treatment against pneumonic plague.
    J Infect Dis. 2019 May 16. pii: 5490663. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. YAN Y, Wang X, Lou P, Hu Z, et al
    A nanoparticle-based HCV vaccine with enhanced potency.
    J Infect Dis. 2019 May 10. pii: 5487910. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. LAIDLAW SM, Dustin LB
    An HCV vaccine on the fly.
    J Infect Dis. 2019 May 10. pii: 5487908. doi: 10.1093.
    PubMed     Text format    


  9. DROPULIC LK, Oestreich MC, Pietz HL, Laing KJ, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus 2 Vaccine, HSV529, in Adults With or Without HSV Infection.
    J Infect Dis. 2019 May 6. pii: 5486075. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. ROSSI SL, Comer JE, Wang E, Azar SR, et al
    Immunogenicity and Efficacy of a Measles Virus-vectored Chikungunya Vaccine in Nonhuman Primates.
    J Infect Dis. 2019 May 3. pii: 5485499. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. AMOAH S, Mishina M, Praphasiri P, Cao W, et al
    Standard dose intradermal influenza vaccine elicits similar cellular immune responses when compared to intramuscular vaccine in HIV-infected or uninfected men.
    J Infect Dis. 2019 May 2. pii: 5482500. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2019
  12. WOESTENBERG PJ, King AJ, Van Benthem BHB, Leussink S, et al
    Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
    J Infect Dis. 2019 Apr 23. pii: 5476422. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. PATRICIA K, Wijmenga-Monsuur AJ, van Houten MA, Veldhuijzen IK, et al
    A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults.
    J Infect Dis. 2019 Apr 23. pii: 5476427. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. HAYDEN CA, Hung CY, Zhang H, Negron A, et al
    Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.
    J Infect Dis. 2019 Apr 23. pii: 5479236. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. KANDASAMY R, Voysey M, Collins S, Berbers G, et al
    Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13.
    J Infect Dis. 2019 Apr 20. pii: 5475435. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. PILISHVILI T
    Pneumococcal conjugate vaccine effects in the United Kingdom: success of vaccine policy and remaining opportunities for prevention.
    J Infect Dis. 2019 Apr 20. pii: 5475438. doi: 10.1093.
    PubMed     Text format    


  17. ATMAR RL, Baehner F, Cramer JP, Lloyd E, et al
    Antibody persistence to two Virus-Like Particle norovirus vaccine candidate formulations in healthy adults: one-year follow-up with memory probe vaccination.
    J Infect Dis. 2019 Apr 18. pii: 5475178. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. BRINKMAN ID, de Wit J, Smits GP, Ten Hulscher HI, et al
    Early measles vaccination during an outbreak in The Netherlands: reduced short and long-term antibody responses in children vaccinated before 12 months of age.
    J Infect Dis. 2019 Apr 11. pii: 5441452. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. SUTTER RW, Cochi SL
    Inactivated Poliovirus Vaccine Supply Shortage: Is There Light at the End of the Tunnel?
    J Infect Dis. 2019 Apr 8. pii: 5432103. doi: 10.1093.
    PubMed     Text format    


  20. HU Y, Wang J, Zeng G, Chu K, et al
    Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
    J Infect Dis. 2019 Apr 8. pii: 5431722. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. CHEN C, van Schaik EJ, Gregory AE, Vigil A, et al
    Chemokine Receptor 7 is Essential for Coxiella burnetii Whole-Cell Vaccine Induced Cellular Immunity but Dispensable for Vaccine Mediated Protective Immunity.
    J Infect Dis. 2019 Apr 2. pii: 5425888. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2019
  22. HASHEM AM, Algaissi A, Agrawal A, Al-Amri SS, et al
    A highly immunogenic, protective and safe adenovirus-based vaccine expressing MERS-CoV S1-CD40L fusion protein in transgenic human DPP4 mouse model.
    J Infect Dis. 2019 Mar 26. pii: 5419855. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. SWANSTROM JA, Nivarthi UK, Patel B, Delacruz MJ, et al
    Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by NIH Monovalent Dengue Virus Vaccines.
    J Infect Dis. 2019 Mar 21. pii: 5416140. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. TEBAS P, Kraynyak KA, Patel A, Maslow JN, et al
    Intradermal SynCon(R) Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
    J Infect Dis. 2019 Mar 19. pii: 5395966. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. ZHANG Z, Liang Z, Zeng J, Zhang J, et al
    Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with recombinant hepatitis B vaccine and group A meningococcal polysaccharide vaccine: a phase IV, open-label, single-center, randomized, non-inferiority tr
    J Infect Dis. 2019 Mar 19. pii: 5395971. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. HUYEN DTT, Mach O, Trung NT, Thai PQ, et al
    Rapid Disappearance of Poliovirus Type 2 Immunity in Young Children Following Withdrawal of Oral Poliovirus Type 2 Containing Vaccine in Vietnam.
    J Infect Dis. 2019 Mar 14. pii: 5380634. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2019
  27. ITURRIZA-GOMARA M, Jere KC, Hungerford D, Bar-Zeev N, et al
    Aetiology of diarrhoea among hospitalised children in Blantyre, Malawi following rotavirus vaccine introduction: a case-control study.
    J Infect Dis. 2019 Feb 28. pii: 5366554. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. BARANIAK I, Kern F, Holenya P, Griffiths P, et al
    Original antigenic sin shapes the immunological repertoire evoked by HCMV gB-MF59 vaccine in seropositive recipients.
    J Infect Dis. 2019 Feb 27. pii: 5366424. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. ANYWAINE Z, Whitworth H, Kaleebu P, Praygod G, et al
    Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania.
    J Infect Dis. 2019 Feb 23. pii: 5364034. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. MUTUA G, Anzala O, Luhn K, Robinson C, et al
    Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya.
    J Infect Dis. 2019 Feb 23. pii: 5364047. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. CRAWT L, Atkinson E, Tedcastle A, Pegg E, et al
    Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays.
    J Infect Dis. 2019 Feb 21. pii: 5351027. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. MODLIN J, Chumakov K
    Sabin Strain Inactivated Polio Vaccine for the Polio Endgame.
    J Infect Dis. 2019 Feb 21. pii: 5351111. doi: 10.1093.
    PubMed     Text format    


  33. SHARMA M, Glasner DR, Watkins H, Puerta-Guardo H, et al
    Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate.
    J Infect Dis. 2019 Feb 19. pii: 5345046. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. BUURMAN ET, Timofeyeva Y, Gu J, Kim JH, et al
    A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the prevention of neonatal group B streptococcal infections by maternal immunization.
    J Infect Dis. 2019 Feb 19. pii: 5336091. doi: 10.1093.
    PubMed     Text format     Abstract available


  35. LELIEVRE JD, Hocqueloux L
    Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.
    J Infect Dis. 2019 Feb 16. pii: 5344456. doi: 10.1093.
    PubMed     Text format     Abstract available


  36. GRAY GC
    Adenovirus 4 and 7 vaccine: New Body Armor for Marine Officer Trainees.
    J Infect Dis. 2019 Feb 6. pii: 5308337. doi: 10.1093.
    PubMed     Text format    


  37. ZELNER J, Petrie JG, Trangucci R, Martin ET, et al
    Effects of sequential influenza A(H1N1)pdm09 vaccination on antibody waning.
    J Infect Dis. 2019 Feb 4. pii: 5306487. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. FOLSCHWEILLER N, Behre U, Dionne M, Durando P, et al
    Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.
    J Infect Dis. 2019 Feb 3. pii: 5306135. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  39. PAULES CI, Fauci AS
    Influenza Vaccines: Good, But We Can Do Better.
    J Infect Dis. 2019 Jan 31. pii: 5304932. doi: 10.1093.
    PubMed     Text format    


  40. SAAD-ROY CM, McDermott AB, Grenfell BT
    Dynamic perspectives on the search for a universal influenza vaccine.
    J Infect Dis. 2019 Jan 31. pii: 5304934. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. CRANK MC, Mascola JR, Graham BS
    Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.
    J Infect Dis. 2019 Jan 31. pii: 5304928. doi: 10.1093.
    PubMed     Text format    


  42. RUDRARAJU R, Mordant F, Subbarao K
    How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304927. doi: 10.1093.
    PubMed     Text format    


  43. ROSS TM
    Universal Influenza Vaccine Approaches Employing Full-Length or Head-only HA Proteins.
    J Infect Dis. 2019 Jan 31. pii: 5304925. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. SAELENS X
    The Role of M2e in the Development of Universal Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304896. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. KANEKIYO M, Ellis D, King NP
    New Vaccine Design and Delivery Technologies.
    J Infect Dis. 2019 Jan 31. pii: 5304933. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. EICHELBERGER MC, Monto AS
    Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection.
    J Infect Dis. 2019 Jan 31. pii: 5304892. doi: 10.1093.
    PubMed     Text format     Abstract available


  47. KRAMMER F, Palese P
    Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain.
    J Infect Dis. 2019 Jan 31. pii: 5304926. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. MORENS DM, Taubenberger JK
    Making Universal Influenza Vaccines: Lessons from the 1918 Pandemic.
    J Infect Dis. 2019 Jan 31. pii: 5304851. doi: 10.1093.
    PubMed     Text format    


  49. ORTIZ JR, Neuzil KM
    Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines.
    J Infect Dis. 2019 Jan 31. pii: 5304930. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. ADLER H, Nikolaou E, Gould K, Hinds J, et al
    Pneumococcal colonization in healthy adult research participants in the conjugate vaccine era, United Kingdom, 2010-2017.
    J Infect Dis. 2019 Jan 28. pii: 5303784. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. BENNETT A, Pollock L, Jere KC, Pitzer VE, et al
    Infrequent Transmission of Monovalent Human Rotavirus Vaccine Virus to Household Contacts of Vaccinated Infants in Malawi.
    J Infect Dis. 2019 Jan 24. pii: 5300242. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. GILKEY MB, Margolis MA
    Human Papillomavirus Vaccination Coverage Gaps in Young Adolescents.
    J Infect Dis. 2019 Jan 17. pii: 5265336. doi: 10.1093.
    PubMed     Text format    


  53. BEDNARCZYK RA, Ellingson MK, Omer SB
    Human Papillomavirus Vaccination Before 13 and 15 Years of Age: Analysis of National Immunization Survey Teen Data.
    J Infect Dis. 2019 Jan 17. pii: 5265326. doi: 10.1093.
    PubMed     Text format     Abstract available


  54. GAMAGE D, Mach O, Ginige S, Weldon WC, et al
    Poliovirus type 2 seroprevalence following full or fractional-dose of inactivated poliovirus vaccine in the period after Sabin type 2 withdrawal in Sri Lanka.
    J Infect Dis. 2019 Jan 11. pii: 5288498. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2018
  55. HOWARD LM, Goll JB, Jensen TL, Hoek KL, et al
    AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures In Human Peripheral Blood Mononuclear Cells.
    J Infect Dis. 2018 Dec 19. pii: 5253567. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. YANG YYM, Wilson RA, Thomas SRL, Kariuki TM, et al
    Micro array-assisted analysis of anti-schistosome glycan antibodies elicited by protective vaccination with irradiated cercariae.
    J Infect Dis. 2018 Dec 18. pii: 5250920. doi: 10.1093.
    PubMed     Text format     Abstract available


  57. FLANNERY B, Fry AM
    Comparing influenza vaccine types: the path towards improved influenza vaccine strategies.
    J Infect Dis. 2018 Dec 18. pii: 5250956. doi: 10.1093.
    PubMed     Text format    


  58. IZURIETA HS, Chillarige Y, Kelman J, Wei Y, et al
    Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017-18.
    J Infect Dis. 2018 Dec 18. pii: 5250955. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. BOLAY FK, Grandits G, Lane HC, Kennedy SB, et al
    PREVAIL I cluster vaccination study with rVSVG-ZEBOV-GP as part of a public health response in Liberia.
    J Infect Dis. 2018 Dec 17. pii: 5250908. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. NG TWY, Cowling BJ, Gao HZ, Thompson MG, et al
    Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis.
    J Infect Dis. 2018 Dec 14. pii: 5247419. doi: 10.1093.
    PubMed     Text format     Abstract available


  61. KEITEL WA, Atmar RL
    Influenza Vaccines after Seven Decades: Still on the Learning Curve.
    J Infect Dis. 2018 Dec 14. pii: 5248489. doi: 10.1093.
    PubMed     Text format    


  62. FERDINANDS JM, Gaglani M, Martin ET, Middleton D, et al
    Prevention of influenza hospitalization among adults in the US, 2015-16: Results from the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).
    J Infect Dis. 2018 Dec 14. pii: 5248488. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. BARTSCH SM, Asti L, Cox S, Durham DP, et al
    What is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks.
    J Infect Dis. 2018 Dec 13. pii: 5244597. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. KAWAI K, Yawn BP
    Risk of Herpes Zoster in Cancer Patients and the Promise of New Vaccines.
    J Infect Dis. 2018 Dec 13. pii: 5234725. doi: 10.1093.
    PubMed     Text format    


  65. ZOST SJ, Wu NC, Hensley SE, Wilson IA, et al
    Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens.
    J Infect Dis. 2018 Dec 9. pii: 5236836. doi: 10.1093.
    PubMed     Text format    


    November 2018
  66. SANYAL M, Holmes TH, Maecker H, Albrecht RA, et al
    Diminished B-cell response after repeat influenza vaccination.
    J Infect Dis. 2018 Nov 28. pii: 5212478. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. POETSCH JH, Dahlke C, Zinser ME, Kasonta R, et al
    Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans.
    J Infect Dis. 2018 Nov 17. pii: 5187947. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. FINN A
    The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.
    J Infect Dis. 2018 Nov 16. pii: 5184715. doi: 10.1093.
    PubMed     Text format    


  69. GERSHON AA, Brooks D, Stevenson DD, Chin WK, et al
    High Constitutive IL-10 Interferes with the Immune Response to Varicella-Zoster Virus (VZV) in Elderly Recipients of Live Attenuated Zoster Vaccine.
    J Infect Dis. 2018 Nov 16. pii: 5184646. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. VENKATRAMAN N, Ndiaye BP, Bowyer G, Wade D, et al
    Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen - ChAd3-EBO-Z followed by MVA-EBO-Z in healthy adults in the UK and Senegal.
    J Infect Dis. 2018 Nov 8. pii: 5164386. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  71. ROSENBERG T, Philipsen BB, Mehlum CS, Dyrvig AK, et al
    Therapeutic use of the HPV vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis.
    J Infect Dis. 2018 Oct 25. pii: 5144565. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. ARMAH GE, Cortese MM, Dennis FE, Yu Y, et al
    Rotavirus Vaccine Take in Infants Is Associated With Secretor Status.
    J Infect Dis. 2018 Oct 24. pii: 5144065. doi: 10.1093.
    PubMed     Text format     Abstract available


  73. BEERNINK PT, Ispasanie E, Lewis LA, Ram S, et al
    A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed Factor H binding protein elicits gonococcal bactericidal antibodies.
    J Infect Dis. 2018 Oct 20. pii: 5139647. doi: 10.1093.
    PubMed     Text format     Abstract available


  74. PATEL A, Reuschel EL, Kraynyak KA, Racine T, et al
    Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.
    J Infect Dis. 2018 Oct 10. pii: 5123708. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. KUDO R, Yamaguchi M, Sekine M, Adachi S, et al
    Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    J Infect Dis. 2018 Oct 9. pii: 5115492. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2018
  76. PRAHARAJ I, Parker EPK, Giri S, Allen DJ, et al
    Influence of non-polio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from south India.
    J Infect Dis. 2018 Sep 24. pii: 5106276. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. RAMANI S, Harris V
    Going Viral! Unraveling the Impact of Non-polio Enteroviruses on Oral Vaccine Responses.
    J Infect Dis. 2018 Sep 24. pii: 5106282. doi: 10.1093.
    PubMed     Text format    


  78. PATEL NP, Vukmanovic-Stejic M, Suarez-Farinas M, Chambers ES, et al
    Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  79. HARPAZ R, van Hoek AJ
    Point-Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  80. GILBERT PB, Luedtke AR
    Statistical Learning Methods to Determine Immune Correlates of Herpes Zoster in Vaccine Efficacy Trials.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  81. WEINBERG A, Kroehl ME, Johnson MJ, Hammes A, et al
    Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  82. TSENG HF, Sy LS
    Use of Real-world Evidence to Evaluate the Effectiveness of Herpes Zoster Vaccine.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  83. CUNNINGHAM AL, Levin MJ
    Herpes Zoster Vaccines.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  84. BREUER J
    Molecular Genetic Insights Into Varicella Zoster Virus (VZV), the vOka Vaccine Strain, and the Pathogenesis of Latency and Reactivation.
    J Infect Dis. 2018;218.
    PubMed     Text format     Abstract available


  85. PARKER EPK, Whitfield H, Baskar C, Giri S, et al
    FUT2 secretor status is not associated with oral poliovirus vaccine immunogenicity in south Indian infants.
    J Infect Dis. 2018 Sep 19. pii: 5102389. doi: 10.1093.
    PubMed     Text format     Abstract available


  86. ARTEMCHUK H, Eriksson T, Poljak M, Surcel HM, et al
    Long-Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow-Up in the Finnish Maternity Cohort.
    J Infect Dis. 2018 Sep 18. pii: 5099444. doi: 10.1093.
    PubMed     Text format     Abstract available


  87. SCHALTZ-BUCHHOLZER F, Biering-Sorensen S, Lund N, Monteiro I, et al
    Early Bacille Calmette-Guerin vaccination, hospitalizations and hospital deaths: Analysis of a secondary outcome in three randomized trials from Guinea-Bissau.
    J Infect Dis. 2018 Sep 18. pii: 5099442. doi: 10.1093.
    PubMed     Text format     Abstract available


  88. CIGLENECKI I, Azman AS, Jamet C, Serafini M, et al
    Progress and Challenges in Using Oral Cholera Vaccines to Control Outbreaks: The Medecins Sans Frontieres Experience.
    J Infect Dis. 2018 Sep 14. pii: 5098246. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. ATMAR RL, Cramer JP, Baehner F, Han C, et al
    An exploratory study of the salivary IgA responses to one dose of a Norovirus VLP candidate vaccine in healthy adults.
    J Infect Dis. 2018 Sep 10. pii: 5094041. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. MARSHALL HS, Clarke M, Heath C, Quinn H, et al
    Severe and complicated varicella and associated genotypes 10 years after introduction of a one dose varicella vaccine program.
    J Infect Dis. 2018 Sep 3. pii: 5089719. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. HARRIS JB
    Cholera: Immunity and Prospects in Vaccine Development.
    J Infect Dis. 2018 Sep 1. pii: 5089248. doi: 10.1093.
    PubMed     Text format     Abstract available


    August 2018
  92. WEINBERG A, Popmihajlov Z, Schmader KE, Johnson MJ, et al
    Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine.
    J Infect Dis. 2018 Aug 28. pii: 5084879. doi: 10.1093.
    PubMed     Text format     Abstract available


  93. LI Z, Chang P, Xu J, Tan C, et al
    A Streptococcus suis live vaccine suppresses streptococcal toxic shock-like syndrome and provides sequence type independent protectionTITLE.
    J Infect Dis. 2018 Aug 27. pii: 5081797. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. CAGIGI A, Ploquin A, Niezold T, Zhou Y, et al
    Vaccine-Mediated Induction of an Ebolavirus Cross-Species Antibody Binding to Conserved Epitopes on the Glycoprotein Heptad Repeat 2/Membrane-Proximal External Junction.
    J Infect Dis. 2018 Aug 22. pii: 5078072. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. CHANOUZAS D, Sagmeister M, Faustini S, Nightingale P, et al
    Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in ANCA-associated vasculitis.
    J Infect Dis. 2018 Aug 9. pii: 5068409. doi: 10.1093.
    PubMed     Text format     Abstract available


  96. LIANG Y, Che Y, Yang B, Zhan F, et al
    Immunogenicity and safety of an F-genotype attenuated mumps vaccine in healthy 8- to 24-month-old children.
    J Infect Dis. 2018 Aug 1. pii: 5063175. doi: 10.1093.
    PubMed     Text format     Abstract available


  97. LAZCANO-PONCE E, Torres-Ibarra L, Cruz-Valdez A, Salmeron J, et al
    Persistence of immunity when using different HPV vaccination schedules and booster dose effects at 5 years post-primary vaccination.
    J Infect Dis. 2018 Aug 1. pii: 5063117. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2018
  98. SUSCHAK JJ, Bagley K, Shoemaker CJ, Six C, et al
    The Genetic Adjuvants Interleukin-12 and Granulocyte-Macrophage Colony Stimulating Factor Enhance the Immunogenicity of an Ebola Virus Deoxyribonucleic Acid Vaccine in Mice.
    J Infect Dis. 2018 Jul 19. pii: 5056373. doi: 10.1093.
    PubMed     Text format     Abstract available


  99. FEIRING B, Laake I, Christiansen IK, Hansen M, et al
    Substantial decline in prevalence of vaccine-type and non-vaccine type HPV in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway.
    J Infect Dis. 2018 Jul 16. pii: 5054086. doi: 10.1093.
    PubMed     Text format     Abstract available


  100. POPPER SJ, Strouts FR, Lindow JC, Cheng HK, et al
    Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers.
    J Infect Dis. 2018 Jul 14. pii: 5053882. doi: 10.1093.
    PubMed     Text format     Abstract available


  101. CAGIGI A, Misasi J, Ploquin A, Stanley DA, et al
    Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.
    J Infect Dis. 2018 Jul 12. pii: 5052389. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. VAN WAGONER N, Fife K, Leone PA, Bernstein DI, et al
    Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital HSV-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-controlled Trial.
    J Infect Dis. 2018 Jul 6. pii: 5049813. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. ANGUIANO-ZARATE SS, Matchett WE, Nehete P, Sastry KJ, et al
    A Replicating Single-cycle Adenovirus Vaccine against Ebola Virus.
    J Infect Dis. 2018 Jul 6. pii: 5049708. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. HOLBROOK MR
    Will a single-cycle Adenovirus vaccine be effective against Ebola virus?
    J Infect Dis. 2018 Jul 6. pii: 5049709. doi: 10.1093.
    PubMed     Text format    


  105. YOUSAFZAI MT
    Role of fractional dose intradermal inactivated poliovirus vaccine in halting polio transmission: finding the missing piece for global polio eradication.
    J Infect Dis. 2018 Jul 5. pii: 5049362. doi: 10.1093.
    PubMed     Text format    


  106. GAMAGE D, Mach O, Palihawadana P, Zhang Y, et al
    Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine.
    J Infect Dis. 2018 Jul 5. pii: 5049361. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  107. WARFIELD KL, Howell KA, Vu H, Geisbert J, et al
    Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.
    J Infect Dis. 2018 Jun 25. pii: 5043486. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. FUENTES S, Ravichandran S, Khurana S
    Antibody Repertoire of Human Polyclonal Antibodies Against Ebola Virus Glycoprotein Generated After Deoxyribonucleic Acid and Protein Vaccination of Transchromosomal Bovines.
    J Infect Dis. 2018 Jun 25. pii: 5043463. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. LIU F, Tzeng WP, Horner L, Kamal RP, et al
    Both Immune Priming and Egg-adaptation in the Vaccine Influence Antibody Responses to Circulating A(H1N1)pdm09 Viruses Following Influenza Vaccination in Adults.
    J Infect Dis. 2018 Jun 21. pii: 5042019. doi: 10.1093.
    PubMed     Text format     Abstract available


  110. SOUCY AM, Hurteau GJ, Metzger DW
    Live vaccination generates both disease tolerance and host resistance during chronic pulmonary infection with highly virulent F. tularensis SchuS4.
    J Infect Dis. 2018 Jun 20. pii: 5040507. doi: 10.1093.
    PubMed     Text format     Abstract available


  111. MESHER D, Panwar K, Thomas SL, Edmundson C, et al
    The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
    J Infect Dis. 2018 Jun 18. pii: 5025126. doi: 10.1093.
    PubMed     Text format     Abstract available


  112. LIU Y, Ye L, Lin F, Gomaa Y, et al
    Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.
    J Infect Dis. 2018 Jun 8. pii: 5034941. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2018
  113. SWANSTROM JA, Henein S, Plante JA, Yount BL, et al
    Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.
    J Infect Dis. 2018;217:1932-1941.
    PubMed     Text format     Abstract available


  114. KAINULAINEN MH, Spengler JR, Welch SR, Coleman-McCray JD, et al
    Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    J Infect Dis. 2018;217:1957-1966.
    PubMed     Text format     Abstract available


  115. PERCIANI CT, Sekhon M, Hundal S, Farah B, et al
    Live-attenuated Zoster Vaccine Boosts VZV-specific Humoral Responses Systemically and at the Cervico-vaginal Mucosa of Kenyan VZV-seropositive Women.
    J Infect Dis. 2018 May 25. pii: 5003463. doi: 10.1093.
    PubMed     Text format     Abstract available


  116. CHAKRABORTY S, Randall A, Vickers TJ, Molina D, et al
    Human experimental challenge with enterotoxigenic Escherichia coli elicits immune responses to canonical and novel antigens relevant to vaccine development.
    J Infect Dis. 2018 May 24. pii: 5003007. doi: 10.1093.
    PubMed     Text format     Abstract available


  117. PAMNANI SJ, Sudenga SL, Rollison DE, Ingles DJ, et al
    Recurrence of Genital Infections with Nine HPV Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) among Men in the HPV Infection in Men (HIM) Study.
    J Infect Dis. 2018 May 24. pii: 5002064. doi: 10.1093.
    PubMed     Text format     Abstract available


  118. BERNSTEIN DI
    Rotavirus Vaccines: Mind Your Ps and Gs.
    J Infect Dis. 2018 May 22. pii: 5001445. doi: 10.1093.
    PubMed     Text format    


  119. ROCZO-FARKAS S, Kirkwood CD, Cowley D, Barnes GL, et al
    The Impact of Rotavirus Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of Australian Surveillance Data.
    J Infect Dis. 2018 May 22. pii: 5001444. doi: 10.1093.
    PubMed     Text format     Abstract available


  120. KABINEH AK, Carr W, Motevalli M, Legardy-Williams J, et al
    Operationalizing International Regulatory Standards in a Limited-Resource Setting During an Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Experience.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  121. CARTER RJ, Senesi RGB, Dawson P, Gassama I, et al
    Participant Retention in a Randomized Clinical Trial in an Outbreak Setting: Lessons From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  122. CONTEH MA, Goldstein ST, Wurie HR, Gidudu J, et al
    Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  123. JARRETT OD, Seward JF, Fombah AE, Lindblad R, et al
    Monitoring Serious Adverse Events in the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  124. SAMAI M, Seward JF, Goldstein ST, Mahon BE, et al
    The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVG-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  125. SCHUCHAT A, Seward JF, Goldstein ST, Mahon BE, et al
    Comment: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format    


  126. CARTER RJ, Idriss A, Widdowson MA, Samai M, et al
    Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  127. FOMBAH AE, Goldstein ST, Jarrett OD, Jalloh MI, et al
    Health Conditions in an Adult Population in Sierra Leone: Data Reported From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  128. EDEM-HOTAH J, McDonald W, Abu PM, Luman ET, et al
    Utilizing Nurses to Staff an Ebola Vaccine Clinical Trial in Sierra Leone during the Ebola Outbreak.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  129. JUSU MO, Glauser G, Seward JF, Bawoh M, et al
    Rapid Establishment of a Cold Chain Capacity of -60 degrees C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone.
    J Infect Dis. 2018;217.
    PubMed     Text format     Abstract available


  130. GARLAND SM, Pitisuttithum P, Ngan HYS, Cho CH, et al
    Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    J Infect Dis. 2018 May 15. pii: 4996119. doi: 10.1093.
    PubMed     Text format     Abstract available


  131. FARMAKI PF, Chini MC, Mangafas NM, Tzanoudaki MT, et al
    Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
    J Infect Dis. 2018 May 2. pii: 4990938. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2018
  132. CARROLL TD, Jegaskanda S, Matzinger SR, Fritts L, et al
    A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus macaques from uncontrolled virus replication after heterosubtypic influenza A virus challenge.
    J Infect Dis. 2018 Apr 26. pii: 4986227. doi: 10.1093.
    PubMed     Text format     Abstract available


  133. JOYCE JC, Carroll TD, Collins ML, Chen MH, et al
    A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.
    J Infect Dis. 2018 Apr 26. pii: 4986788. doi: 10.1093.
    PubMed     Text format     Abstract available


  134. AMLABU E, Mensah-Brown H, Nyarko PB, Akuh OA, et al
    Functional Characterization of Plasmodium falciparum Surface Related Antigen (PfSRA) as a Potential Blood-Stage Vaccine Target.
    J Infect Dis. 2018 Apr 18. pii: 4975396. doi: 10.1093.
    PubMed     Text format     Abstract available


  135. DE VRIES RD, Altenburg AF, Nieuwkoop NJ, de Bruin E, et al
    Induction of Cross-Clade Antibody and T-Cell Responses by an MVA-Based Influenza H5N1 Vaccine in a Randomized Phase I/IIa Clinical Trial.
    J Infect Dis. 2018 Apr 18. pii: 4975691. doi: 10.1093.
    PubMed     Text format     Abstract available


  136. LIN KY, Hsieh SM, Sheng WH, Lo YC, et al
    Comparable serologic responses to 2 different combinations of inactivated HAV vaccines in HIV-positive patients during the acute hepatitis A outbreak in Taiwan.
    J Infect Dis. 2018 Apr 16. pii: 4972613. doi: 10.1093.
    PubMed     Text format     Abstract available


  137. BADEN LR, Walsh SR, Seaman MS, Cohen YZ, et al
    First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
    J Infect Dis. 2018 Apr 13. pii: 4969772. doi: 10.1093.
    PubMed     Text format     Abstract available


  138. HAIDARA FC, Tapia MD, Sow SO, Doumbia M, et al
    Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Co-Administered with Measles, Yellow Fever and Meningitis A Vaccines in 9-month-old Malian Infants.
    J Infect Dis. 2018 Apr 12. pii: 4969416. doi: 10.1093.
    PubMed     Text format     Abstract available


  139. ZIMMERMANN P, Finn A, Curtis N
    Does BCG Vaccination Protect Against Non-Tuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.
    J Infect Dis. 2018 Apr 7. pii: 4964710. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  140. LANGLEY JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, et al
    A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study.
    J Infect Dis. 2018 Mar 30. pii: 4956800. doi: 10.1093.
    PubMed     Text format     Abstract available


  141. MANNING JE, Morens DM, Kamhawi S, Valenzuela JG, et al
    Mosquito saliva: the hope for a universal arbovirus vaccine?
    J Infect Dis. 2018 Mar 29. pii: 4956143. doi: 10.1093.
    PubMed     Text format     Abstract available


  142. GUO Q, Chan JF, Poon VK, Wu S, et al
    Immunization with a Novel Human type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models.
    J Infect Dis. 2018 Mar 29. pii: 4956202. doi: 10.1093.
    PubMed     Text format     Abstract available


  143. FENG G, Boyle MJ, Cross N, Chan JA, et al
    Human immunization with a polymorphic malaria vaccine candidate induced antibodies to conserved epitopes that promote functional antibodies to multiple parasite strains.
    J Infect Dis. 2018 Mar 23. pii: 4952401. doi: 10.1093.
    PubMed     Text format     Abstract available


  144. PATEL EU, Grabowski MK, Eisenberg AL, Packman ZR, et al
    Increases in Human Papillomavirus Vaccination Among Adolescent and Young Adult Males in the United States, 2011-2016.
    J Infect Dis. 2018 Mar 23. pii: 4951824. doi: 10.1093.
    PubMed     Text format     Abstract available


  145. ANGRISANO F, Blagborough AM
    Understanding human-derived antibodies generated by polymorphic malaria vaccine against merozoite surface protein 2.
    J Infect Dis. 2018 Mar 23. pii: 4952403. doi: 10.1093.
    PubMed     Text format    


  146. SCHLEISS MR
    Searching for a Serological Correlate of Protection for a CMV Vaccine.
    J Infect Dis. 2018 Mar 8. pii: 4924674. doi: 10.1093.
    PubMed     Text format    


  147. BARANIAK I, Kropff B, McLean GR, Pichon S, et al
    Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine with MF59: Anti-AD2 Levels Correlate with Protection from Viremia.
    J Infect Dis. 2018 Mar 8. pii: 4924673. doi: 10.1093.
    PubMed     Text format     Abstract available


  148. ROGAWSKI ET, Platts-Mills JA, Colgate ER, Haque R, et al
    Quantifying the Impact of Natural Immunity on Rotavirus Vaccine Efficacy Estimates: A Clinical Trial in Dhaka, Bangladesh (PROVIDE) and a Simulation Study.
    J Infect Dis. 2018;217:861-868.
    PubMed     Text format     Abstract available


  149. BUCHHOLZ UJ, Cunningham CK, Muresan P, Gnanashanmugam D, et al
    Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    J Infect Dis. 2018 Mar 2. pii: 4917539. doi: 10.1093.
    PubMed     Text format     Abstract available


  150. POLACK FP
    Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus.
    J Infect Dis. 2018 Mar 2. pii: 4917537. doi: 10.1093.
    PubMed     Text format    


  151. MCFARLAND EJ, Karron RA, Muresan P, Cunningham CK, et al
    Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.
    J Infect Dis. 2018 Mar 2. pii: 4917538. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  152. ERBELDING EJ, Post D, Stemmy E, Roberts PC, et al
    A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
    J Infect Dis. 2018 Feb 28. pii: 4904047. doi: 10.1093.
    PubMed     Text format     Abstract available


  153. CUNNINGHAM AL, Heineman TC, Lal H, Godeaux O, et al
    Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged >/=50 Years.
    J Infect Dis. 2018 Feb 26. pii: 4911103. doi: 10.1093.
    PubMed     Text format     Abstract available


  154. YOUNG-XU Y, Van Aalst R, Mahmud SM, Rothman KJ, et al
    Relative Vaccine Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines among Veterans Health Administration Patients.
    J Infect Dis. 2018 Feb 14. pii: 4858294. doi: 10.1093.
    PubMed     Text format     Abstract available


  155. KOJIC EM, Conley L, Bush T, Cu-Uvin S, et al
    Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types covered by Current HPV Vaccines among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study
    J Infect Dis. 2018 Feb 14. pii: 4857222. doi: 10.1093.
    PubMed     Text format     Abstract available


  156. BIERING-SORENSEN S, Jensen KJ, Monterio I, Ravn H, et al
    Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth Weight Boys: Observations From Randomized Trials.
    J Infect Dis. 2018;217:759-766.
    PubMed     Text format     Abstract available


  157. LO NC, Gupta R, Stanaway JD, Garrett DO, et al
    Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    J Infect Dis. 2018 Feb 12. pii: 4851280. doi: 10.1093.
    PubMed     Text format     Abstract available


  158. ZENKLUSEN I, Jongo S, Abdulla S, Ramadhani K, et al
    Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies.
    J Infect Dis. 2018 Feb 8. pii: 4845622. doi: 10.1093.
    PubMed     Text format     Abstract available


  159. MACHALEK DA, Garland SM, Brotherton JML, Bateson D, et al
    Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination.
    J Infect Dis. 2018 Feb 7. pii: 4841780. doi: 10.1093.
    PubMed     Text format     Abstract available


  160. FREYNE B, Donath S, Germano S, Gardiner K, et al
    Neonatal BCG vaccination influences cytokine responses to Toll-like receptor ligands and heterologous antigens.
    J Infect Dis. 2018 Feb 3. pii: 4837044. doi: 10.1093.
    PubMed     Text format     Abstract available


  161. DONKEN R, King AJ, Bogaards JA, Woestenberg PJ, et al
    High effectiveness of the bivalent HPV vaccine up to six years post-vaccination against incident and persistent HPV infections in young Dutch females.
    J Infect Dis. 2018 Feb 2. pii: 4835373. doi: 10.1093.
    PubMed     Text format     Abstract available


  162. LEVIN MJ, Cai GY, Lee KS, Rouphael NG, et al
    Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835758. doi: 10.1093.
    PubMed     Text format     Abstract available


  163. POLLOCK KGJ
    Sustained cross-protection of the bivalent HPV vaccine.
    J Infect Dis. 2018 Feb 2. pii: 4835375. doi: 10.1093.
    PubMed     Text format    


  164. BERAN J, Lickliter JD, Schwarz TF, Johnson C, et al
    Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in non-pregnant women: results from two phase II trials.
    J Infect Dis. 2018 Feb 1. pii: 4833521. doi: 10.1093.
    PubMed     Text format     Abstract available


  165. SHANG L, Smith AJ, Duan L, Perkey KE, et al
    Vaccine-associated maintenance of epithelial integrity correlated with protection against virus entry.
    J Infect Dis. 2018 Feb 1. pii: 4833184. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  166. LEE B, Dickson DM, deCamp AC, Colgate ER, et al
    Histoblood Group Antigen Phenotype Determines Susceptibility to Genotype-specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy.
    J Infect Dis. 2018 Jan 30. pii: 4829672. doi: 10.1093.
    PubMed     Text format     Abstract available


  167. MALHOTRA I, LaBeaud AD, Morris N, McKibben M, et al
    Cord Blood Anti-Parasite IL-10 as Risk Marker for Compromised Vaccine Immunogenicity in Early Childhood.
    J Infect Dis. 2018 Jan 30. pii: 4829506. doi: 10.1093.
    PubMed     Text format     Abstract available


  168. JUNG J, Ko SJ, Oh HS, Moon SM, et al
    Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome.
    J Infect Dis. 2018 Jan 24. pii: 4823438. doi: 10.1093.
    PubMed     Text format     Abstract available


  169. CHENG AC, Subbarao K
    Epidemiological Data on the Effectiveness of Influenza Vaccine-Another Piece of the Puzzle.
    J Infect Dis. 2018 Jan 18. pii: 4816917. doi: 10.1093.
    PubMed     Text format    


  170. FLANNERY B, Smith C, Garten RJ, Levine MZ, et al
    Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.
    J Infect Dis. 2018 Jan 18. pii: 4816916. doi: 10.1093.
    PubMed     Text format     Abstract available


  171. CHIU SS, Kwan MYW, Feng S, Wong JSC, et al
    Influenza vaccine effectiveness against influenza A(H3N2) hospitalizations in children in Hong Kong in a prolonged season, 2016/17.
    J Infect Dis. 2018 Jan 16. pii: 4810661. doi: 10.1093.
    PubMed     Text format     Abstract available


  172. KAPIL P, Papin JF, Wolf RF, Zimmerman LI, et al
    Maternal Vaccination with a Mono-component Pertussis Toxoid Vaccine is Sufficient to Protect Infants in a Baboon Model of Whooping Cough.
    J Infect Dis. 2018 Jan 15. pii: 4808590. doi: 10.1093.
    PubMed     Text format     Abstract available


  173. CAPEDING MR, Alberto ER, Bouckenooghe A, Laot TM, et al
    Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    J Infect Dis. 2018 Jan 9. pii: 4794746. doi: 10.1093.
    PubMed     Text format     Abstract available


  174. PRINGLE KD, Burke RM, Steiner CA, Parashar UD, et al
    Trends in Rate of Seizure-Associated Hospitalizations Among Children <5 Years Old Before and After Rotavirus Vaccine Introduction in the United Sates, 2000-2013.
    J Infect Dis. 2018 Jan 9. pii: 4796788. doi: 10.1093.
    PubMed     Text format     Abstract available


  175. FONG Y, Shen X, Ashley VC, Deal A, et al
    Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505.
    J Infect Dis. 2018 Jan 8. pii: 4792964. doi: 10.1093.
    PubMed     Text format     Abstract available


  176. BRICKLEY EB, Strauch CB, Wieland-Alter WF, Connor RI, et al
    Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
    J Infect Dis. 2018 Jan 3. pii: 4788281. doi: 10.1093.
    PubMed     Text format     Abstract available


  177. SUTTER RW
    Unraveling the Mucosal Immunity of Inactivated Poliovirus Vaccine.
    J Infect Dis. 2018 Jan 3. pii: 4788256. doi: 10.1093.
    PubMed     Text format    


  178. GIRI S, Kumar N, Dhanapal P, Venkatesan J, et al
    The quantity of vaccine poliovirus shedding determines the titer of the serum neutralizing antibody response in Indian children vaccinated with oral vaccine.
    J Infect Dis. 2018 Jan 2. pii: 4782493. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  179. RAMILO O, Rodriguez-Fernandez R, Mejias A
    One Step Forward in the Road Toward a Universal Influenza Vaccine.
    J Infect Dis. 2017;217:1-2.
    PubMed     Text format    


  180. MAJUMDAR M, Klapsa D, Wilton T, Akello J, et al
    Isolation of vaccine-like poliovirus strains in sewage samples from the UK.
    J Infect Dis. 2017 Dec 22. pii: 4772162. doi: 10.1093.
    PubMed     Text format     Abstract available


  181. MEYER M, Huang E, Yuzhakov O, Ramanathan P, et al
    Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease.
    J Infect Dis. 2017 Dec 21. pii: 4770157. doi: 10.1093.
    PubMed     Text format     Abstract available


  182. DURBIN AP, Whitehead SS
    Zika Vaccines: Role for Controlled Human Infection.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  183. MORABITO KM, Graham BS
    Zika Virus Vaccine Development.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  184. GRUBER MF, Farizo KM, Pratt RD, Fink DL, et al
    Clinical Development Strategies and Considerations for Zika Vaccine Licensure.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  185. OSUNA CE, Whitney JB
    Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  186. PRIYAMVADA L, Suthar MS, Ahmed R, Wrammert J, et al
    Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  187. MORENS DM, Fauci AS
    Pandemic Zika: A Formidable Challenge to Medicine and Public Health.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  188. VOIGT EA, Haralambieva IH, Larrabee BL, Kennedy RB, et al
    Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination.
    J Infect Dis. 2017 Dec 14. pii: 4743250. doi: 10.1093.
    PubMed     Text format     Abstract available


  189. MADARAS-KELLY K, Remington R, Hruza H, Xu D, et al
    The Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines in Preventing Post-Influenza Deaths.
    J Infect Dis. 2017 Dec 9. pii: 4718125. doi: 10.1093.
    PubMed     Text format    


  190. YOUNG B, Sadarangani S, Jiang L, Wilder-Smith A, et al
    The Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis and Meta-regression of Test-Negative Design Case-control Studies.
    J Infect Dis. 2017 Dec 6. pii: 4694421. doi: 10.1093.
    PubMed     Text format     Abstract available


  191. OHFUJI S, Deguchi M, Tachibana D, Koyama M, et al
    Protective effect of maternal influenza vaccination on influenza in their infants: a prospective cohort study.
    J Infect Dis. 2017 Dec 5. pii: 4693945. doi: 10.1093.
    PubMed     Text format     Abstract available


  192. BURN C, Ramsey N, Garforth SJ, Almo S, et al
    An HSV-2 single-cycle candidate vaccine deleted in glycoprotein D, DeltagD-2, protects male mice from lethal skin challenge with clinical isolates of HSV-1 and HSV-2.
    J Infect Dis. 2017 Dec 5. pii: 4693944. doi: 10.1093.
    PubMed     Text format     Abstract available


  193. LIU WC, Lin CS, Yeh CC, Wu HY, et al
    Effect of Influenza Vaccination Against Postoperative Pneumonia and Mortality for Geriatric Patients Receiving Major Surgery: A Nationwide Matched Study.
    J Infect Dis. 2017 Dec 5. pii: 4690590. doi: 10.1093.
    PubMed     Text format     Abstract available


  194. HAGAN JE, Takashima Y, Sarankhuu A, Dashpagma O, et al
    Risk Factors for Measles Virus Infection Among Adults During a Large Outbreak in Postelimination Era in Mongolia, 2015.
    J Infect Dis. 2017;216:1187-1195.
    PubMed     Text format     Abstract available


    November 2017
  195. MOODIE Z, Juraska M, Huang Y, Zhuang Y, et al
    Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
    J Infect Dis. 2017 Nov 29. pii: 4675250. doi: 10.1093.
    PubMed     Text format     Abstract available


  196. SCHERER EM, Smith RA, Carter JJ, Wipf GC, et al
    Analysis of memory B cell responses reveals suboptimal dosing schedule of a licensed vaccine.
    J Infect Dis. 2017 Nov 24. pii: 4657105. doi: 10.1093.
    PubMed     Text format     Abstract available


  197. HIRAMATSU H, Suzuki R, Nagatani A, Boda H, et al
    Rotavirus vaccination can be performed without viral dissemination in the Neonatal Intensive Care Unit.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  198. DREW DR, Sanders PR, Weiss G, Gilson PR, et al
    Functional conservation of the AMA1 host-cell invasion ligand between P. falciparum and P. vivax: a novel platform to accelerate vaccine and drug development.
    J Infect Dis. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format     Abstract available


  199. CHEN HL, Wen WH, Chang MH
    Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  200. OLDFIELD NJ, Green LR, Parkhill J, Bayliss CD, et al
    Limited impact of adolescent meningococcal ACWY vaccination on group W carriage in university students.
    J Infect Dis. 2017 Nov 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  201. LEROUX-ROELS G, Cramer JP, Mendelman PM, Sherwood J, et al
    Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  202. WOESTENBERG PJ, King AJ, van Benthem BHB, Donken R, et al
    Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors.
    J Infect Dis. 2017 Nov 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  203. NOVAKOVIC D, Cheng ATL, Zurynski Y, Booy R, et al
    A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program.
    J Infect Dis. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  204. DONOVAN B, Callander D
    Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue.
    J Infect Dis. 2017 Nov 9. doi: 10.1093.
    PubMed     Text format    


  205. SALEEM AF, Mach O, Yousafzai MT, Khan A, et al
    Immunogenicity of Different Routine Poliovirus Vaccination Schedules: a Randomized Controlled Trial, Karachi, Pakistan.
    J Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  206. VANDERVEN HA, Jegaskanda S, Wines BD, Hogarth PM, et al
    Antibody-dependent cellular cytotoxicity (ADCC) responses to seasonal influenza vaccination in older adults.
    J Infect Dis. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  207. LIN SM, Jang AY, Zhi Y, Gao S, et al
    Immunization with a Latch Peptide Provides Serotype-Independent Protection against Group B Streptococcus Infection in Mice.
    J Infect Dis. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  208. SICRE DE FONTBRUNE F, Arnaud C, Cheminant M, Boulay A, et al
    Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy.
    J Infect Dis. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  209. SKOWRONSKI DM, Chambers C, De Serres G
    Selection bias in the assessment of frailty and its role in influenza vaccine effectiveness evaluation among elderly adults.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format    


  210. SKOWRONSKI DM, Chambers C, Sabaiduc S, De Serres G, et al
    Beyond antigenic match: possible agent-host and immuno-epidemiological influences on influenza vaccine effectiveness during the 2015-16 season in Canada.
    J Infect Dis. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  211. BELONGIA E
    Beyond Antigenic Match: Moving Toward Greater Understanding of Influenza Vaccine Effectiveness.
    J Infect Dis. 2017 Sep 27. doi: 10.1093.
    PubMed     Text format    


  212. OXMAN MN, Harbecke R, Koelle DM
    Clinical Usage of the Candidate Adjuvanted HZ/su Zoster Vaccine: re-vaccination of recipients of live attenuated zoster vaccine and co-administration with a seasonal influenza vaccine.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format    


  213. SCHWARZ TF, Aggarwal N, Moeckesch B, Schenkenberger I, et al
    Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  214. GRUPPING K, Campora L, Douha M, Heineman TC, et al
    Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine.
    J Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  215. FALLOON J, Yu J, Esser MT, Villafana T, et al
    An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  216. NICHOLSON E, Piedra PA
    Local Versus Global Enterovirus (EV) Surveillance: A Discussion For The Need for Active Surveillance To Guide EV A71 Vaccines.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  217. LANGLEY JM
    Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues.
    J Infect Dis. 2017 Sep 23. doi: 10.1093.
    PubMed     Text format    


  218. LEVINE MZ, Holiday C, Liu F, Jefferson S, et al
    Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  219. JONES EN, Amoah S, Cao W, Sambhara S, et al
    An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  220. PODDIGHE D
    2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine.
    J Infect Dis. 2017;216:782-783.
    PubMed     Text format    


  221. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


  222. TORRESI J, Richmond PC, Heron LG, Qiao M, et al
    Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  223. DROLET M, Laprise JF, Brotherton JML, Donovan B, et al
    The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation.
    J Infect Dis. 2017 Sep 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  224. DUNKLE LM, Izikson R, Patriarca PA, Goldenthal KL, et al
    Randomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.
    J Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  225. AKE JA, Schuetz A, Pegu P, Wieczorek L, et al
    Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  226. NING T, Wolfe A, Nie J, Huang W, et al
    Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  227. OLIVER SE, Unger ER, Lewis R, McDaniel D, et al
    Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    J Infect Dis. 2017;216:594-603.
    PubMed     Text format     Abstract available


    August 2017
  228. MCNAMARA LA, Thomas JD, MacNeil J, Chang HY, et al
    Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp - Oregon, 2015-2016.
    J Infect Dis. 2017 Aug 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  229. LEHTINEN T, Soderlund-Strand A, Petaja T, Eriksson T, et al
    Human papillomavirus (HPV) prevalence in adolescent males four years post HPV16/18 vaccination.
    J Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  230. MODROF J, Tille B, Farcet MR, McVey J, et al
    Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins:is an Increase by Re-Vaccination of Plasma Donors possible?
    J Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  231. NEUZIL KM, Chen WH
    Influenza Vaccines for Older Persons: Progress and Pitfalls.
    J Infect Dis. 2017;216:397-398.
    PubMed     Text format    


  232. ANDREW MK, Shinde V, Ye L, Hatchette T, et al
    The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
    J Infect Dis. 2017;216:405-414.
    PubMed     Text format     Abstract available


  233. VAN BEEK J, Veenhoven RH, Bruin JP, van Boxtel RAJ, et al
    Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections.
    J Infect Dis. 2017;216:415-424.
    PubMed     Text format     Abstract available


  234. MCELHANEY JE, McNeil SA
    Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults.
    J Infect Dis. 2017;216:399-401.
    PubMed     Text format    


  235. LIBRATY DH
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017;216:502-503.
    PubMed     Text format    


    July 2017
  236. PATEL M, Cochi S
    Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  237. ZIPURSKY S, Vandelaer J, Brooks A, Dietz V, et al
    Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  238. PEDREIRA C, Thrush E, Jauregui B
    Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    March 2017
  239. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017;215:841-843.
    PubMed     Text format    


  240. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
    J Infect Dis. 2017;215:844-846.
    PubMed     Text format    


  241. MONTO AS
    Moving Toward Improved Influenza Vaccines.
    J Infect Dis. 2017 Mar 2. doi: 10.1093.
    PubMed     Text format    


    December 2016
  242. HADLER JL
    Christmas-New Year influenza lull: not too late for vaccination.
    J Infect Dis. 2016 Dec 28. pii: jiw643. doi: 10.1093.
    PubMed     Text format    


    May 2016
  243. VIROJANAPIROM P, Lumlertdacha B, Wipattanakitchareon A, Hemachudha T, et al
    T-705 as a potential therapeutic in rabies.
    J Infect Dis. 2016.
    PubMed     Text format    


    February 2016
  244. MASCITELLI L, Goldstein MR
    How regulatory T cells induction by statin drugs may impair influenza vaccine immunogenicity and effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format    


  245. TITA AT, Andrews WW
    Influenza Vaccination and Antiviral Therapy in Pregnant Women.
    J Infect Dis. 2016.
    PubMed     Text format    


    January 2016
  246. VAN DAMME P
    Long-term Protection After Hepatitis B Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: